BMO Capital analyst Kostas Biliouris upgraded Ionis Pharmaceuticals (IONS) to Outperform from Market Perform with a price target of $70, up from $40. The firm says olezarsen’s better than expected acute pancreatitis. benefit outperformed expectations and can render the drug a fully-owned blockbuster for Ionis in the U.S. In addition, BMO expects the company’s upcoming readouts in 2026 to be positive. Meanwhile, Ionis’s Angelman program could deliver a multi-billion dollar opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Promising Investment: Ionis Pharmaceuticals’ Olezarsen Surpasses Expectations with Phase 3 CORE Trial Success
- Why Did IONIS Stock (IONS) Surge to a Four-Year High?
- Ionis Pharmaceuticals price target raised to $78 from $58 at Barclays
- Ionis Pharmaceuticals: Strong Buy Rating Backed by Promising Phase 3 Study Results for Olezarsen
- Morgan Stanley ups Ionis target on ‘best-case scenario’ data